Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

DLBCL-microenvironment interactions: cytokine profiling and ECM-mediated ibrutinib resistance in a 3D bone-based model.

Medical oncology (Northwood, London, England)·2026

Same author

Utility of Optical Genome Mapping in the Characterisation of the Global Genomic Architecture of Paediatric Central Nervous System Tumours: A Pilot Study.

Neuropathology and applied neurobiology·2026

Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026

Same author

Ill Fate of Rectal Mucinous Adenocarcinoma: A Defect in Immunosurveillance or a Mucin Coating Effect?-The IMMUNOREACT 20 Study.

Cancers·2026

Same author

Erratum to "Pathologists in Venice - Real world cases for an immersive training experience": Education, gaming, and show. <i>Journal of Pathology Informatics</i>, Volume 17, 2025, 100418.

Journal of pathology informatics·2026

Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

PML down-regulation in soft tissue sarcomas.

Bruno Vincenzi¹, Giuseppe Perrone, Daniele Santini

¹Department of Oncology, University Campus Bio-Medico, Rome, Italy.

Journal of Cellular Physiology

|June 26, 2010

Summary

Promyelocytic leukemia (PML) gene expression is altered in several soft tissue sarcomas. PML is significantly down-regulated in synovial sarcoma, myofibroblastic sarcoma, and certain liposarcoma subtypes, suggesting a potential role in these aggressive cancers.

Related Experiment Videos

Last Updated: Jun 12, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

Oncology
Molecular Biology
Cancer Research

Background:

The role of the promyelocytic leukemia (PML) gene in tumorigenesis is not fully understood.
PML gene expression has not been previously investigated in soft tissue sarcomas (STS).

Purpose of the Study:

To investigate differences in PML protein expression between various STS subtypes and normal surrounding tissues.
To explore the potential of PML as a biomarker in STS.

Main Methods:

Immunohistochemistry was used to assess PML protein expression.
Six histologic types of STS were analyzed: synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma.
Expression levels were compared between tumor samples and corresponding normal adjacent tissues.

Main Results:

PML was significantly down-regulated in synovial sarcoma and myofibroblastic sarcoma.
Angiosarcoma showed a significant difference in PML expression compared to normal tissue.
Myxoid and dedifferentiated liposarcomas exhibited significantly lower PML expression, while pleomorphic liposarcoma did not show a significant difference.

Conclusions:

PML protein expression is altered in specific soft tissue sarcoma subtypes.
Down-regulation of PML may be implicated in the pathogenesis of certain STS.
Further research is needed to validate these findings and explore PML's prognostic value in aggressive STS.